760results about "Animal cells" patented technology

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to TMPRSS2, and methods of using such antibodies and fragments to treat or prevent viral infection (eg, influenza virus infection). [Selected Figure] Figure 2

To provide universal antigen presenting cells.SOLUTION: Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.SELECTED DRAWING: Figure 1A

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The invention provides an anti-PD-1 antibody, a CAR-T cell, and a preparation method and application thereof. The anti-PD-1 antibody comprises LCDR-1-3 as shown in SEQ ID NO: 1-3 and HCDR-1-3 as shown in SEQ ID NO: 4-6, respectively. The CAR-T cell expresses a novel element for efficiently blocking the PD-1, and the element is a single-chain antibody for targeting the PD-1 in a cell membrane anchoring manner. And the chimeric antigen receptor and the cell membrane anchored anti-PD-1 scFv are connected by a 2A cleavage protein. The membrane anchor type anti-PD-1 scFv expressed by the CAR-T cell can almost completely block the expression of PD-1 on the surface of a T cell membrane, and further block a signal channel combined with PD-1 / PD-L1, so that the capability of T cell depletion caused by antagonism tumor of the CAR-T cell is enhanced, and the purpose of enhancing the anti-tumor effect of the CAR-T cell is achieved.

To provide a method for simply and efficiently evaluating the inducibility of a foreign matter response reaction in the skin of a test sample without using an animal, and to provide a substance having the inhibitory properties of the foreign matter response reaction in the skin and a method for searching the same.SOLUTION: The method includes a step of bringing keratinocytes transformed with a vector having an enhancer sequence containing a foreign body-responsive sequence and a sequence encoding a reporter protein downstream of the enhancer sequence into contact with a solution containing a test sample, a step of measuring the expression level of the reporter protein in the keratinocytes, and a step of evaluating the inducibility of a foreign body response reaction of the test sample in the skin based on the expression level of the reporter protein. The problem is solved by providing an agent for suppressing foreign matter response reaction in the skin containing fregula 1 found by the search method.SELECTED DRAWING: Figure 3

To provide immunotherapy that prevents or minimizes the failure of immunotherapy treatment due to the emergence of antigen-loss escape mutations in cancer cells, etc. [Solution] A bispecific chimeric antigen receptor comprising (a) an antigen-specific target-directed region containing an antigen-specific single-chain Fv(scFv) fragment that binds to at least two different antigens, (b) an extracellular spacer domain, (c) a transmembrane domain, (d) at least one costimulatory domain, and (e) an intracellular signaling domain, which is to be co-expressed with a therapeutic regulatory substance such as truncated epidermal growth factor receptor (EGFRt).

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

This invention provides engineered natural killer (NK) cells and methods for producing engineered NK cells. [Solution] The present invention provides engineered natural killer (NK) cells, which are genetically modified to reduce the expression, activity, and / or signaling of the FcRγ chain in the cells. The engineered NK cells and compositions comprising the engineered NK cells are useful for treating diseases such as cancer.

A cell transplanting kit includes a transplant including a cell group and a cell transplanting device. The cell transplanting device includes a needle-shaped portion that extends in a shape of a tube, and an aspiration portion configured to aspirate an interior of the needle-shaped portion. The needle-shaped portion is configured to attract the transplant by aspiration by the aspiration portion and take the transplant into the interior. The aspiration portion is configured to create an aspiration pressure in a range of −100 kPa to −0.1 kPa. The transplant includes a protection portion in a form of a gel covering at least a part of the cell group. The transplant has an outer diameter that is greater than or equal to a minimum value of the inner diameter of the needle-shaped portion. The protection portion has a jelly strength of greater than or equal to 100 g.

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody is capable of binding to the BDCA2 antigen with high specificity, exhibits high affinity, effectively inhibits CpG-A-stimulated secretion of IFNα and IgM by PBMCs, showing potential as a therapeutic agent for autoimmune diseases.

The present disclosure relates to a method for the production of CD4 + CD4 produced by genetically modifying T cells IL-10 / CAR Provide cell populations (autologous or allogeneic single donor and allogeneic polydonor). In addition, CD4 IL-10 / CAR Methods for generating CD4 cells and for immune tolerance IL-10 / CAR Methods of using the cells to treat GvHD, cell and organ transplantation, cancer, and other autoimmune and inflammatory disorders are provided.

To provide a cell culture system that can be installed a culture bag and culture cells, can be easily carried in the state that various tools necessary for the culture are bundled, and can subject the culture bag to an observation with a general-purpose microscope.SOLUTION: Provided is a cell culture system for culturing cells in a culture bag made of soft packaging material, comprising: a culture unit having a notch portion for mounting a bag container comprising a pressing member for pressing the bag; a bag disposed on the unit in a bag container; a medium container for supplying medium to the bag; a waste liquid container to which the medium is discharged from the bag; a liquid delivery means disposed on a member that connects the bag and the culture medium container; and a liquid sending means disposed on a member connecting the bag and the waste liquid container, the distance from the bottom of the unit to the culture surface being less than 20 mm, the liquid thickness of the culture medium being uniformed by pressing the bag with the pressing member, and the surface of the unit, the upper and lower surfaces of the pressing member, and the upper and culture surfaces of the bag being substantially parallel.SELECTED DRAWING: Figure 12

While immune checkpoint block (ICB) therapy has significantly improved outcomes for metastatic melanoma, most patients do not achieve long-term benefits. Previous studies have suggested that treatment failure is partly due to insufficient immune recognition of tumor antigens (TAs). Cancer vaccines may potentially offer a complementary approach to enhance anti-tumor immunity and act synergistically with ICIs. Novel tumor antigens shared by the majority of melanoma cells are described herein. Some of the tumor antigens described herein are derived from abnormally expressed non-mutant genomic sequences, such as intronic and intergenetic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, and vaccines derived from these tumor antigens are described. The use of tumor antigens, nucleic acids, compositions, cells, and vaccines for the treatment of melanoma is also described.

Provided are anti-Nectin-4 antibodies or antigen-binding fragments thereof, antibody conjugates comprising the same, and uses thereof in the manufacture of medicaments, particularly in the manufacture of medicaments for treating and / or preventing cancer. [Solution] Provided is an antibody or antigen-binding fragment thereof that specifically binds to Nectin-4, which comprises three heavy chain CDRs, each containing a specific sequence defined according to the Chothia numbering system, and three light chain CDRs, each containing another specific sequence defined according to the Chothia numbering system.

Provided are an antibody specifically binding to CD276 and use thereof. Specifically provided are a CD276 antibody or an antigen binding fragment thereof, and the like. Also provided are a polynucleotide encoding the CD276 antibody, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a preparation method and a transformed cell thereof. The provided CD276 antibody can bind to CD276 protein at a high affinity and a high specificity, can be prepared into a target recognition domain of CAR-T cells, and can also be prepared into a bispecific T-cell engager (BiTE) to exert an anti-tumor effect for preventing or treating cancers.

Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and / or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and / or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region. The therapeutic agent achieves synergistic therapeutic effect.

Described herein are RPE cells engineered to secrete GLA protein, as well as compositions, pharmaceutical formulations, and implantable devices comprising the engineered RPE cells, and methods of making and using them to treat Fabry disease.

The present invention relates to recombinant vectors, particularly recombinant vectors comprising a molecular adjuvant. The invention extends to pharmaceutical compositions and vaccines comprising the recombinant vector, to their use in therapy, and processes for making such pharmaceutical compositions. The invention also encompasses novel cell lines for producing the recombinant vectors.

The present invention pertains to: a granzyme B variant having enhanced protease activity and / or enhanced tolerance against an inhibitory factor; a polynucleotide encoding the granzyme B variant; a cell expressing the granzyme B variant; a pharmaceutical composition comprising the cell expressing the granzyme B variant; and a pharmaceutical composition comprising the granzyme B variant. In some embodiments, the pharmaceutical composition can be used in combination with a cell expressing a chimeric receptor and / or an antigen-binding molecule.

When expressed recombinantly on the T cell surface, HLA-A * Provided herein are T cell receptors (TCRs) capable of recognizing the MAGE-B2 derived peptide GVYDGEEHSV (SEQ ID NO: 1) when presented by 02:01 sufficiently to activate recombinant T cells. Certain TCRs provided herein are also capable of recognizing the MAGE-A4 derived peptide GVYDGREHTV (SEQ ID NO: 2) sufficiently to activate recombinant T cells. Importantly, the exemplary TCRs provided herein have been thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissues, and for alloreactivity.

This provides a novel tumor-specific antigen (TSA) shared by the majority of ovarian tumors. [Solution] Most (>80%) of the TSAs described herein are derived from abnormally expressed non-mutant genomic sequences, such as intronic sequences and intergenetic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, and vaccines derived from these TSAs are described. The use of TSAs, nucleic acids, compositions, cells, and vaccines for the treatment of ovarian cancer is also described.

Therapeutic agents that can place bulky proteins, such as CD45, CD148, and CD43, at the center of the cellular interface between graft cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells) are disclosed, as are methods of their use and products made with such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immunological synapses (including physiological SMACs). They also result in the continuous dephosphorylation of signaling pathways.

An anti-CD94 antibody and a use thereof. The antibody comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, wherein: the amino acid sequences of the heavy chain CDR1, CDR2, and CDR3 respectively have at least 80% homology with the sequences represented by SEQ ID NOs 1, 2, and 3, and the amino acid sequences of the light chain CDR1, CDR2, and CDR3 respectively have at least 80% homology with the sequences represented by SEQ ID NOs 4, 5, and 6. The present antibody can bind to human CD94 proteins, relieve CD94 / NKG2A-mediated immunosuppression, promote the activation of T cells, and can effectively treat and prevent diseases related to CD94 mediation.

To provide methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions comprising the same and reaction mixtures.SOLUTION: A method for expanding and / or activating a population of immune cells (e.g., immune effector cells) includes introducing a nucleic acid encoding a first chimeric antigen receptor (CAR) molecule into an immune cell population, under conditions suitable for transient expression of the CAR molecule, thereby producing a first CAR-expressing cell population, where the CAR molecule comprises an antigen binding domain of an antigen molecule; and contacting the first CAR-expressing cell population with a ligand of the CAR antigen binding domain selected from a cognate antigen molecule (e.g., a recombinant antigen) or an anti-idiotypic antibody molecule, under conditions such that immune cell expansion and / or activation occurs, thereby producing an expanded and / or activated immune cell population.SELECTED DRAWING: None